000154416 001__ 154416
000154416 005__ 20240229123100.0
000154416 0247_ $$2doi$$a10.1002/ijc.32999
000154416 0247_ $$2pmid$$apmid:32243586
000154416 0247_ $$2ISSN$$a0020-7136
000154416 0247_ $$2ISSN$$a1097-0215
000154416 0247_ $$2altmetric$$aaltmetric:79156641
000154416 037__ $$aDKFZ-2020-00747
000154416 041__ $$aeng
000154416 082__ $$a610
000154416 1001_ $$aIdahl, Annika$$b0
000154416 245__ $$aSerologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort.
000154416 260__ $$aBognor Regis$$bWiley-Liss$$c2020
000154416 3367_ $$2DRIVER$$aarticle
000154416 3367_ $$2DataCite$$aOutput Types/Journal article
000154416 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1635317919_25420$$xReview Article
000154416 3367_ $$2BibTeX$$aARTICLE
000154416 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000154416 3367_ $$00$$2EndNote$$aJournal Article
000154416 500__ $$a147(8):2042-2052#LA:C020#
000154416 520__ $$aA substantial proportion of epithelial ovarian cancer (EOC) arises in the fallopian tube and other epithelia of the upper genital tract; these epithelia may incur damage and neoplastic transformation following sexually transmitted infections (STI) and pelvic inflammatory disease. We investigated the hypothesis that past STI infection, particularly Chlamydia trachomatis, is associated with higher EOC risk in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort including 791 cases and 1,669 matched controls. Serum antibodies against C. trachomatis, Mycoplasma genitalium, herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV) 16, 18 and 45 were assessed using multiplex fluorescent bead-based serology. Conditional logistic regression was used to estimate relative risks (RR) and 95% confidence intervals [CI] comparing women with positive vs. negative serology. A total of 40% of the study population was seropositive to at least one STI. Positive serology to C. trachomatis Pgp3 antibodies was not associated with EOC risk overall, but with higher risk of the mucinous histotype (RR=2.30 [95% CI=1.22-4.32]). Positive serology for chlamydia heat shock protein 60 (cHSP60-1) was associated with higher risk of EOC overall (1.36 [1.13-1.64]) and with the serous subtype (1.44 [1.12-1.85]). None of the other evaluated STIs were associated with EOC risk overall; however, HSV-2 was associated with higher risk of endometrioid EOC (2.35 [1.24-4.43]). The findings of this study suggest a potential role of C. trachomatis in the carcinogenesis of serous and mucinous EOC, while HSV-2 might promote the development of endometrioid disease.
000154416 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000154416 588__ $$aDataset connected to CrossRef, PubMed,
000154416 7001_ $$0P:(DE-HGF)0$$aCornet, Charlotte Le$$b1
000154416 7001_ $$0P:(DE-HGF)0$$aMaldonado, Sandra González$$b2
000154416 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b3$$udkfz
000154416 7001_ $$0P:(DE-He78)540833b33724d8def638cce2f0b4e187$$aBender, Noemi$$b4$$udkfz
000154416 7001_ $$aTjønneland, Anne$$b5
000154416 7001_ $$aHansen, Louise$$b6
000154416 7001_ $$00000-0002-5956-5693$$aBoutron-Ruault, Marie-Christine$$b7
000154416 7001_ $$aFournier, Agnès$$b8
000154416 7001_ $$00000-0002-4557-3772$$aKvaskoff, Marina$$b9
000154416 7001_ $$aBoeing, Heiner$$b10
000154416 7001_ $$aTrichopoulou, Antonia$$b11
000154416 7001_ $$aValanou, Elisavet$$b12
000154416 7001_ $$aPeppa, Eleni$$b13
000154416 7001_ $$aPalli, Domenico$$b14
000154416 7001_ $$aAgnoli, Claudia$$b15
000154416 7001_ $$aMattiello, Amalia$$b16
000154416 7001_ $$aTumino, Rosario$$b17
000154416 7001_ $$00000-0002-8008-5096$$aSacerdote, Carlotta$$b18
000154416 7001_ $$aOnland-Moret, N Charlotte$$b19
000154416 7001_ $$aGram, Inger T$$b20
000154416 7001_ $$00000-0003-2237-0128$$aWeiderpass, Elisabete$$b21
000154416 7001_ $$aQuirós, J Ramón$$b22
000154416 7001_ $$00000-0001-5256-0163$$aDuell, Eric J$$b23
000154416 7001_ $$aSánchez, Maria-Jose$$b24
000154416 7001_ $$aChirlaque, Maria-Dolores$$b25
000154416 7001_ $$aBarricarte, Aurelio$$b26
000154416 7001_ $$aGil, Leire$$b27
000154416 7001_ $$aBrändstedt, Jenny$$b28
000154416 7001_ $$aRiesbeck, Kristian$$b29
000154416 7001_ $$aLundin, Eva$$b30
000154416 7001_ $$aKhaw, Kay-Tee$$b31
000154416 7001_ $$aPerez-Cornago, Aurora$$b32
000154416 7001_ $$aGunter, Marc J$$b33
000154416 7001_ $$aDossus, Laure$$b34
000154416 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b35$$udkfz
000154416 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b36$$eLast author$$udkfz
000154416 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.32999$$n8$$p2042-2052$$tInternational journal of cancer$$v147$$x0020-7136$$y2020
000154416 909CO $$ooai:inrepo02.dkfz.de:154416$$pVDB
000154416 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000154416 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000154416 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000154416 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)540833b33724d8def638cce2f0b4e187$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000154416 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b35$$kDKFZ
000154416 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b36$$kDKFZ
000154416 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000154416 9141_ $$y2020
000154416 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000154416 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000154416 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000154416 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000154416 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2017
000154416 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000154416 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000154416 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000154416 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000154416 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000154416 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000154416 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2017
000154416 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000154416 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000154416 9201_ $$0I:(DE-He78)F022-20160331$$kF022$$lInfektionen und Krebs-Epidemiologie$$x1
000154416 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lInfektionen und Krebs-Epidemiologie$$x2
000154416 980__ $$ajournal
000154416 980__ $$aVDB
000154416 980__ $$aI:(DE-He78)C020-20160331
000154416 980__ $$aI:(DE-He78)F022-20160331
000154416 980__ $$aI:(DE-He78)F020-20160331
000154416 980__ $$aUNRESTRICTED